Abstract
Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16
Highlights
Bone marrow toxicity is a major dose-limiting factor in the clinical use of adriamycin and VP16 (VP16-213, etoposide)
We have studied the effect of verapamil at a range of concentrations on the sensitivity of human bone marrow granulocyte-macrophage stem cells (CFU-GM) to adriamycin and VP16
Lymphocyte conditioned medium was produced by light density peripheral blood mononuclear cells (PBNCs) from normal subjects obtained using Ficoll-diatrizoate separation
Summary
Bone marrow toxicity is a major dose-limiting factor in the clinical use of adriamycin (doxorubicin) and VP16 (VP16-213, etoposide). We have studied the effect of verapamil at a range of concentrations (including concentrations achievable in vivo) on the sensitivity of human bone marrow granulocyte-macrophage stem cells (CFU-GM) to adriamycin and VP16. In preliminary studies (subjects 5 and 6) colony number was determined in the presence and absence of the solvent used to dissolve the VP16 (i.e. 0.025% ethanol, final concentration).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
